| Name | Stufflebean Pharmacy |
|---|---|
| Organization Name | Jordan Drug Inc |
| Location | 1031 Grand Ave, Beattyville, Kentucky 41311 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (606) 464-3396 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.
Currently, about 30 per cent of patients who receive oral surgery have their cancer recur. But a new, Canada-wide surgical trial using a new approach to remove tumours and pre-cancerous cells from the mouths of those diagnosed with early-stage oral cancer offers new hope for patients.
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."
Inflammation of a tendon triggered by calcium deposits, or calcific tendinitis, can effectively be treated with a simple and cost effective percutaneous method according to a recent study conducted by researchers from the Hospital de Basurto in Bilbao, Spain.
› Verified 5 days ago
| NPI Number | 1689602799 |
| Organization Name | JORDAN DRUG, INC. |
| Doing Business As | STUFFLEBEAN PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1031 Grand Ave., Beattyville, KY 41311 |
| Phone Number | 606-464-3396 |
News Archive
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.
Currently, about 30 per cent of patients who receive oral surgery have their cancer recur. But a new, Canada-wide surgical trial using a new approach to remove tumours and pre-cancerous cells from the mouths of those diagnosed with early-stage oral cancer offers new hope for patients.
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."
Inflammation of a tendon triggered by calcium deposits, or calcific tendinitis, can effectively be treated with a simple and cost effective percutaneous method according to a recent study conducted by researchers from the Hospital de Basurto in Bilbao, Spain.
› Verified 5 days ago
News Archive
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.
Currently, about 30 per cent of patients who receive oral surgery have their cancer recur. But a new, Canada-wide surgical trial using a new approach to remove tumours and pre-cancerous cells from the mouths of those diagnosed with early-stage oral cancer offers new hope for patients.
VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.
Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."
Inflammation of a tendon triggered by calcium deposits, or calcific tendinitis, can effectively be treated with a simple and cost effective percutaneous method according to a recent study conducted by researchers from the Hospital de Basurto in Bilbao, Spain.
› Verified 5 days ago
Stufflebean Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1031 Grand Ave, Beattyville, Kentucky 41311 Phone: (606) 464-3396 | |
Village Apothecary Type: Durable Medical Equipment & Medical Supplies Supplier Location: 110 River Dr, Beattyville, Kentucky 41311 Phone: (606) 464-3656 | |
Omnicare Of Beattyville Type: Medicare Supplier Location: 1071 Highway 11 N, Beattyville, Kentucky 41311 Phone: (606) 464-0941 | |
Walgreens #18427 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 31 Big Hill Dr, Beattyville, Kentucky 41311 Phone: (606) 464-2581 |